Genomic Health Announces New Results From Prostate Cancer Study

Genomic Health Announces New Results From Prostate Cancer Study
Genomic Health, Inc. has announced that results from nine studies of Oncotype DX® in prostate, breast, and renal cancers will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid. This will be the first presentation of very promising results from an additional large independent clinical validation study of the Oncotype DX prostate

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *